Documents

Sequora expands edge-AI reach as estimated cash runway stands at 3.95 quarters.

Edge AI and neuromorphic solutions are fueling growth, with bookings and offerings set to expand.

Edge AI growth drives strong chip sales and partnerships, with a solid cash position and roadmap progress.

Revenue up 19% but net loss widened as R&D and operating costs rose; AKD1500 production milestone achieved.

Strategic growth, financial targets, and governance dominated the AGM, with robust shareholder engagement.

Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.

Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.

$35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.

Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.

Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.

Revenue soared 859% and net loss narrowed, with new funding and partnerships fueling growth.

Customer receipts surged and cash burn improved, supporting ongoing growth and innovation.

AGM focused on product innovation, commercial growth, and shareholder engagement challenges.

Q1 2025 saw BrainChip secure key contracts and maintain strong liquidity for future growth.

Revenue up 72% and net loss reduced, with strong capital raises and edge AI focus for 2025.

Closed 2024 with US$20M cash, new defense contracts, and Akida Pico launch for edge AI.

Cash position strengthened to US$25.6M, supporting commercialization and product development.

Cash outflows improved, R&D consolidated, and new collaborations drive commercialization efforts.

The roadmap targets lower-energy edge AI, chained chips for LLMs and broader model support.

US$12.96M in quarter-end cash as Akida commercialization advanced across edge and space.

Akida targets edge AI with an integrated platform and IP-led commercial model.